JP2003513012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003513012A5 JP2003513012A5 JP2001514978A JP2001514978A JP2003513012A5 JP 2003513012 A5 JP2003513012 A5 JP 2003513012A5 JP 2001514978 A JP2001514978 A JP 2001514978A JP 2001514978 A JP2001514978 A JP 2001514978A JP 2003513012 A5 JP2003513012 A5 JP 2003513012A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- nhl
- bone marrow
- lymphoma
- stated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 24
- 210000001185 bone marrow Anatomy 0.000 description 14
- 230000003902 lesion Effects 0.000 description 12
- 239000008194 pharmaceutical composition Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 208000003950 B-cell lymphoma Diseases 0.000 description 7
- 229960004641 rituximab Drugs 0.000 description 7
- 239000012634 fragment Substances 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 238000011363 radioimmunotherapy Methods 0.000 description 3
- 208000002008 AIDS-Related Lymphoma Diseases 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 2
- 206010025312 Lymphoma AIDS related Diseases 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 201000003444 follicular lymphoma Diseases 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 238000004980 dosimetry Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- NYNAFINLHQEHKU-UHFFFAOYSA-N methyl 1-(4-{[(2,4-diaminopteridin-6-yl)methyl]amino}benzoyl)piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C(=O)C(C=C1)=CC=C1NCC1=CN=C(N=C(N)N=C2N)C2=N1 NYNAFINLHQEHKU-UHFFFAOYSA-N 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14828799P | 1999-08-11 | 1999-08-11 | |
| US60/148,287 | 1999-08-11 | ||
| PCT/US2000/040459 WO2001010462A1 (en) | 1999-08-11 | 2000-07-25 | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003513012A JP2003513012A (ja) | 2003-04-08 |
| JP2003513012A5 true JP2003513012A5 (enExample) | 2007-06-28 |
Family
ID=22525101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001514978A Pending JP2003513012A (ja) | 1999-08-11 | 2000-07-25 | 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1207906A4 (enExample) |
| JP (1) | JP2003513012A (enExample) |
| CN (2) | CN101259270A (enExample) |
| AU (1) | AU784971B2 (enExample) |
| CA (1) | CA2378646A1 (enExample) |
| MX (1) | MXPA02001398A (enExample) |
| MY (1) | MY136635A (enExample) |
| NO (1) | NO20020639L (enExample) |
| TW (1) | TWI279233B (enExample) |
| WO (1) | WO2001010462A1 (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL146005A0 (en) | 1999-05-07 | 2002-07-25 | Genentech Inc | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| PT1558648E (pt) | 2002-10-17 | 2012-04-23 | Genmab As | Anticorpos monoclonais humanos contra cd20 |
| AR042485A1 (es) | 2002-12-16 | 2005-06-22 | Genentech Inc | Anticuerpo humanizado que se une al cd20 humano |
| MXPA05010778A (es) | 2003-04-09 | 2005-12-12 | Genentech Inc | Terapia para enfermedad autoinmune en un paciente con una respuesta inadecuada a un inhibidor tnf-alfa. |
| KR101412271B1 (ko) | 2003-05-09 | 2014-06-25 | 듀크 유니버시티 | Ｃｄ２０-특이적 항체 및 이를 이용한 방법 |
| NZ543712A (en) | 2003-06-05 | 2008-06-30 | Genentech Inc | Combination therapy for B cell disorders |
| TR201809892T4 (tr) | 2003-11-05 | 2018-07-23 | Roche Glycart Ag | Fc reseptörüne bağlanma afinitesi ve artırılmış efektör fonksiyonu bulunan antijen bağlayan moleküller. |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| AU2005249566B2 (en) | 2004-06-04 | 2010-11-11 | Genentech, Inc. | Method for treating multiple sclerosis |
| DK2213683T3 (da) | 2004-08-04 | 2013-09-02 | Mentrik Biotech Llc | VARIANT-Fc-REGIONER |
| CN101223448B (zh) | 2005-05-20 | 2012-01-18 | 健泰科生物技术公司 | 来自自身免疫病受试者的生物学样品的预处理 |
| PT1912675E (pt) | 2005-07-25 | 2014-05-09 | Emergent Product Dev Seattle | Moléculas de ligaçao especificas para cd37 e especificas para cd20 |
| US20080213273A1 (en) | 2005-07-25 | 2008-09-04 | Trubion Pharmaceuticals Inc. | Single dose use of CD20-specific binding molecules |
| MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
| ES2618543T3 (es) | 2005-11-23 | 2017-06-21 | Genentech, Inc. | Métodos y composiciones relacionados con ensayos de linfocitos B |
| MX380352B (es) | 2006-06-12 | 2025-03-12 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| HUE046992T2 (hu) | 2007-07-09 | 2020-04-28 | Genentech Inc | Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során |
| EP2200631A1 (en) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease |
| US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| EP2077281A1 (en) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
| RS51975B (sr) | 2008-04-11 | 2012-02-29 | Emergent Product Development Seattle Llc. | Cd37 imunoterapeutski proizvod i njegova kombinacija sa bifunkcionalnim hemoterapeutskim sredstvom |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
| BRPI0923579A2 (pt) * | 2008-12-22 | 2020-01-14 | Millennium Pharm Inc | combinação de inibidores de aurora quinase e anticorpos anti-cd20 |
| JO3434B1 (ar) | 2009-07-31 | 2019-10-20 | Millennium Pharm Inc | مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري |
| SI2464725T2 (sl) | 2009-08-11 | 2025-06-30 | F. Hoffmann-La Roche Ag | Proizvodnja beljakovin v medijih za celične kulture brez glutamina |
| EP2533810B1 (en) | 2010-02-10 | 2016-10-12 | ImmunoGen, Inc. | Cd20 antibodies and uses thereof |
| WO2011103089A1 (en) | 2010-02-19 | 2011-08-25 | Millennium Pharmaceuticals, Inc. | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6--methoxyphenyl)-5h -pyrimido[5,4-d][2]benzazepin-2yl]amino}-2-methoxybenzoate |
| US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
| US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
| CA2907726A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase |
| WO2016118353A1 (en) * | 2015-01-23 | 2016-07-28 | Immunomedics, Inc. | Combination therapy with anti-cd74 and anti-cd20 antibodies in patients with relapsed and refractory b-cell non-hodgkin's lymphoma |
| LT3303373T (lt) | 2015-05-30 | 2020-07-10 | Molecular Templates, Inc. | Deimunizuoto shiga toksino a subvieneto karkasai ir juos apimančios ląstelės taikinio molekulės |
| UA123053C2 (uk) | 2015-06-24 | 2021-02-10 | Ф. Хоффманн-Ля Рош Аг | Антитіло до рецептора трансферину зі спеціально підібраною афінністю |
| BR112018005573A2 (pt) | 2015-09-21 | 2019-01-22 | Aptevo Research And Development Llc | ?polipeptídeos de ligação a cd3? |
| MA43023A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps de récepteur de la transferrine humaine/anti-humaine cd20 bispécifique et leurs procédés d'utilisation |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| MX2019003029A (es) * | 2016-09-16 | 2019-09-13 | Nordic Nanovector Asa | Tratamiento de linfoma no hodgkin usando lilotomab y 177lu-lilotomab satetraxetano. |
| CN108421048B (zh) * | 2016-09-28 | 2021-04-20 | 首都医科大学附属北京世纪坛医院 | 纳米活性碳靶向药物递送系统、制备方法及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT752248E (pt) * | 1992-11-13 | 2001-01-31 | Idec Pharma Corp | Aplicacao terapeutica de anticorpos quimericos e marcados radioactivamente contra antigenios de diferenciacao restrita de linfocitos b humanos para o tratamento do linfoma de celulas b |
| US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
| DE69939939D1 (de) * | 1998-08-11 | 2009-01-02 | Idec Pharma Corp | Kombinationstherapien gegen b-zell-lymphome beinhaltend die verabreichung von anti-cd20-antikörpern |
| US6451284B1 (en) * | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
| US8557244B1 (en) * | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
-
2000
- 2000-07-25 JP JP2001514978A patent/JP2003513012A/ja active Pending
- 2000-07-25 EP EP00965561A patent/EP1207906A4/en not_active Withdrawn
- 2000-07-25 AU AU76260/00A patent/AU784971B2/en not_active Expired
- 2000-07-25 CN CNA2008100921383A patent/CN101259270A/zh active Pending
- 2000-07-25 CN CNB008116644A patent/CN100389825C/zh not_active Expired - Lifetime
- 2000-07-25 MX MXPA02001398A patent/MXPA02001398A/es active IP Right Grant
- 2000-07-25 CA CA002378646A patent/CA2378646A1/en not_active Abandoned
- 2000-07-25 WO PCT/US2000/040459 patent/WO2001010462A1/en not_active Ceased
- 2000-08-03 MY MYPI20003551A patent/MY136635A/en unknown
- 2000-08-10 TW TW089116114A patent/TWI279233B/zh not_active IP Right Cessation
-
2002
- 2002-02-08 NO NO20020639A patent/NO20020639L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003513012A5 (enExample) | ||
| JP2003513012A (ja) | 抗ｃｄ２０抗体による骨髄病変を伴う非ホジキンリンパ腫を有する患者の治療 | |
| CA2350064C (en) | Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants | |
| Olsson et al. | Early oral contraceptive use and breast cancer among premenopausal women: final report from a study in southern Sweden | |
| Esmaeli et al. | Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma | |
| JP2003506414A5 (enExample) | ||
| CA2378574A1 (en) | Treatment of intermediate-and high-grade non-hodgkins lymphoma with anti-cd20 antibody | |
| CA2378584A1 (en) | New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy | |
| JP2005515182A (ja) | 抗腫瘍剤により誘導される心臓毒性を処置するためのデクスラゾキサン | |
| Hart et al. | One‐day vath (vinblastine, adriamycin, thiotepa, and halotestin) therapy for advanced breast cancer refractory to chemotherapy | |
| Raut et al. | Unusual gingival presentation of post-transplantation lymphoproliferative disorder: a case report and review of the literature | |
| Borghaei et al. | Safety and efficacy of radioimmunotherapy with yttrium 90 ibritumomab tiuxetan (Zevalin) | |
| Lee et al. | Eosinophilic granuloma in the anterior mandible mimicking radicular cyst | |
| Martin et al. | Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab | |
| Lo et al. | Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy? | |
| Hiddemann et al. | Mantle cell lymphoma: therapeutic strategies are different from CLL | |
| Butty et al. | Chronic lymphocytic leukemia–associated membranous glomerulopathy: Remission with fludarabine | |
| Morgenroth et al. | Auger electron emitter against multiple myeloma—targeted endo-radio-therapy with 125I-labeled thymidine analogue 5-iodo-4′-thio-2′-deoxyuridine | |
| Omura et al. | Temporary anti-cancer & anti-pain effects of mechanical stimulation of any one of 3 front teeth (1st incisor, 2nd incisor, & canine) of right & left side of upper & lower jaws and their possible mechanism, & relatively long term disappearance of pain & cancer parameters by one optimal dose of DHEA, Astragalus, Boswellia Serrata, often with press needle stimulation of True ST. 36 | |
| Fountzilas et al. | High-dose epirubicin as a single agent in the treatment of patients with advanced breast cancer | |
| DeNardo | with Immunoconjugate | |
| Furman et al. | Testicular relapse in children with acute nonlymphoblastic leukemia | |
| MX2007000327A (es) | Tratamiento del linfoma de celulas b. | |
| Pan et al. | CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas | |
| TWI280137B (en) | Treatment of intermediate-and high-grade non-Hodgkins lymphoma with anti-CD20 antibody |